Literature DB >> 6841195

Interstitial therapy of perineal and gynecological malignancies.

A Martinez, P Herstein, J Portnuff.   

Abstract

Thirty-five patients, 38 to 88 years of age, were treated with 125-Iodine or 192-Iridium interstitial implants at Stanford University Medical Center between July 1974, and December, 1978. There were 25 primary epithelial malignancies, eight extensions from intrapelvic organs and two metastatic tumors (hypernephroma and Hodgkin's disease). The involved sites were: urethra (6 patients); vulva (9 patients); vagina (8 patients); anus (7 patients); cervix (5 patients). Implantation was usually performed to treat evident or microscopic disease in conjunction with external beam pelvic treatment with or without local excision. Computerized implant preplanning was used. 125-Iodine seeds were inserted either directly or within absorbable suture Polyglactin 910; 192-Iridium in nylon carriers was placed by suture or transperineal template. Two patients were lost to follow-up leaving 33 patients, 27 of whom are alive and free of local disease from 37 to 76 months. The overall local control rate was 88%, or 29/33 patients. All four local recurrences appeared before 24 months. Minor complications included: 10 patients with transient mucositis, four with superficial ulcers, and one patient with infection at the implanted site. Two major complications occurred: a necrotic rectal ulcer requiring a colostomy and a contracted, painful bladder necessitating a urinary diversion. We conclude that in selected cases interstitial irradiation provides good local control of perineal and gynecological malignancies with low morbidity in this elderly and quite often fragile group of patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6841195     DOI: 10.1016/0360-3016(83)90306-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  1 in total

1.  Use of transrectal ultrasound for high dose rate interstitial brachytherapy for patients of carcinoma of uterine cervix.

Authors:  Daya Nand Sharma; Goura Kisor Rath; Sanjay Thulkar; Sunesh Kumar; Vellaiyan Subramani; Parmod Kumar Julka
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.